RxDoctor Payments Data

Krista Hess

Acute Care · Nags Head, NCNPI 1982395547

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.

$2,562in general payments, 2019–2025

Across 133 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$485
  • Novartis$392
  • Merck$308
  • United Therapeutics Corporation$225
  • Actelion Pharmaceuticals US, Inc.$221
  • Boehringer Ingelheim$211
  • plus $720 from 11 others

What the payments were for

  • Food & beverage$2,49097%
  • Education$723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,562 in reported general payments places this provider in the 85th percentile of 312 acute care providers in North Carolina.

See all acute care providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$99,664
XareltoRivaroxaban50$61,092
EntrestoSacubitril/Valsartan66$60,549
JardianceEmpagliflozin26$31,906
FarxigaDapagliflozin Propanediol32$19,314
Repatha SureclickEvolocumab17$15,017
BrilintaTicagrelor21$10,100
Nebivolol Hcl83$3,042
Metoprolol Succinate148$1,673
Amiodarone Hcl18$1,388
Ezetimibe33$973
Flecainide Acetate30$922
Valsartan40$819
Rosuvastatin Calcium92$744
Amlodipine Besylate120$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$99,66486 claims
NovartisEntresto$392$60,54966 claims
Boehringer IngelheimJardiance$211$31,90626 claims
AstraZenecaFarxiga, Brilinta$485$29,41453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 acute care providers in North Carolina.

Other acute care in Nags Head

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →